Latest stories

  • in

    Akums gets CDSCO Panel nod for Phase III CT of FDC Moxifloxacin, Nepafenac ophthalmic solution

    New Delhi: The drug major Akum Pharmaceutical has got the green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct the Phase III clinical trial study of the fixed-dose combination of Moxifloxacin plus Nepafenac ophthalmic solution. This came after the firm presented the revised Phase III […] More

  • in

    0.1% water-free cyclosporine solution superior to vehicle on ocular surface in dry eye disease: ESSENCE 2 trial.

    0.1% water-free cyclosporine solution superior to vehicle on ocular surface in dry eye disease: ESSENCE 2 trial.

    Essence 2 randomized clinical trial found that usage of 0.1% water-free cyclosporine solution yielded superior results as it produced early therapeutic effects on the ocular surface when compared to vehicle in dry eye disease patients. The trial results confirmed the ESSENCE 1 trial results and were published in the journal JAMA Ophthalmology.   Dry eye disease […] More

  • in

    USFDA approves Zydus Lifesciences Tavaborole Topical Solution to treat fungal toenail infections

    USFDA approves Zydus Lifesciences Tavaborole Topical Solution to treat fungal toenail infections

    Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Tavaborole Topical Solution, 5% (USRLD: Kerydin Topical Solution). Tavaborole topical solution is indicated to treat fungal toenail infections. These are the infections that may cause nail discoloration, splitting, or pain. The drug will be […] More

  • in

    Looking for an Ayurvedic solution to diabetes? Try sadabahar

    Diabetes, especially type 2, has become a growing concern across the globe. It was found by World Heath Organization (WHO) that the number of people with this chronic disease shot up from 108 million in 1980 to more than 420 million in 2014. As per WHO, over 95 percent of people with this disease have […] More